Pesquisas alternativas:
drug codes » drug code (Expandir a Pesquisa), drug comes (Expandir a Pesquisa), drug copies (Expandir a Pesquisa)
drug doses » drug disease (Expandir a Pesquisa)
devel ther » novel ther (Expandir a Pesquisa), level theory (Expandir a Pesquisa), develop them (Expandir a Pesquisa)
drug dose » drug dosage (Expandir a Pesquisa)
drug dev » drug deal (Expandir a Pesquisa), drug diet (Expandir a Pesquisa), drug does (Expandir a Pesquisa)
drug de » drug dna (Expandir a Pesquisa)
drug codes » drug code (Expandir a Pesquisa), drug comes (Expandir a Pesquisa), drug copies (Expandir a Pesquisa)
drug doses » drug disease (Expandir a Pesquisa)
devel ther » novel ther (Expandir a Pesquisa), level theory (Expandir a Pesquisa), develop them (Expandir a Pesquisa)
drug dose » drug dosage (Expandir a Pesquisa)
drug dev » drug deal (Expandir a Pesquisa), drug diet (Expandir a Pesquisa), drug does (Expandir a Pesquisa)
drug de » drug dna (Expandir a Pesquisa)
1
Por Huang, Peixin, Lee, Mark W, Sadrerafi, Keivan, Heruth, Daniel P, Zhang, Li Q, Maulik, Dev, Ye, Shui Qing
Publicado no Drug Des Devel Ther (2017)
Obter o texto integralPublicado no Drug Des Devel Ther (2017)
Obter o texto integral
Obter o texto integral
Artigo
2
Por Park, Gab-jin, Bae, Soo Hyeon, Park, Wan-Su, Han, Seunghoon, Park, Min-Ho, Shin, Seok-Ho, Shin, Young G, Yim, Dong-Seok
Publicado no Drug Des Devel Ther (2017)
“...PURPOSE: A microdose drug–drug interaction (DDI) study may be a valuable tool for anticipating drug...”Publicado no Drug Des Devel Ther (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
3
Por Scheinberg, Morton, Pott Júnior, Henrique, Macêdo, Eduardo de Almeida, Bocchi de Oliveira, Monalisa Fernanda, Ecclissato, Christina, Amazonas, Roberto Bleuel
Publicado no Drug Des Devel Ther (2018)
“...PURPOSE: This study investigated the safety and efficacy of fixed-dose combination tablets...”Publicado no Drug Des Devel Ther (2018)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
4
Por Lee, Jieon, Rhee, Su-jin, Lee, SeungHwan, Yu, Kyung-Sang
Publicado no Drug Des Devel Ther (2018)
“... dose or as multiple doses to healthy Caucasians. METHODS: Thirty-six subjects were enrolled...”Publicado no Drug Des Devel Ther (2018)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
5
Por Smith, William B, Mannaert, Erik, Verhaeghe, Tom, Kerstens, René, Vandeplassche, Lieve, Van de Velde, Vera
Publicado em 2012
“...)), and severe RI (≤24 mL/min/1.73 m(2)). All received a single oral dose of prucalopride 2 mg. RESULTS: Thirty...”Publicado em 2012
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
6
Por Martínez González, Javier, Monreal, Mayte, Ayani Almagia, Ignacio, Llaudó Garín, Jordi, Ochoa Díaz de Monasterioguren, Lourdes, Gutierro Adúriz, Ibón
Publicado no Drug Des Devel Ther (2018)
“... enoxaparin to the reference drug, and to assess its safety and tolerability in healthy volunteers. PATIENTS...”Publicado no Drug Des Devel Ther (2018)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
7
Por de Leeuw, Erik PH
Publicado em 2014
“... compound that targets Lipid II is described that acts against multi-drug resistant isolates of A. baumannii...”Publicado em 2014
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
8
Por Lee, Jieon, Yoon, Seonghae, Shin, Donghoon, Han, HyeKyung, An, Hyungmi, Lee, Jongtae, Lim, Kyoung Soo, Yu, Kyung-Sang, Lee, Howard
Publicado em 2014
“... nomograms may be required in patients with IE, particularly for once-daily dosing. Therapeutic drug...”Publicado em 2014
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
9
Por Gavazzoni, Mara, Gorga, Elio, Derosa, Giuseppe, Maffioli, Pamela, Metra, Marco, Raddino, Riccardo
Publicado no Drug Des Devel Ther (2017)
“...BACKGROUND AND AIM: Clinical benefits of early high-dose statin therapy after acute coronary...”Publicado no Drug Des Devel Ther (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
10
11
Por Barbarash, Olga, Gruzdeva, Olga, Uchasova, Evgenya, Belik, Ekaterina, Dyleva, Yulia, Karetnikova, Victoria
Publicado no Drug Des Devel Ther (2015)
“..., resulted in a decrease in free fatty acid levels. The positive effect of low-dose atorvastatin (20 mg/day...”Publicado no Drug Des Devel Ther (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
12
Por Kim, Yo Han, Choi, Hee Youn, Noh, Yook-Hwan, Lee, Shi Hyang, Lim, Hyeong-Seok, Kim, Chin, Bae, Kyun-Seop
Publicado no Drug Des Devel Ther (2015)
“... and high blood pressure. The aim of this study was to investigate the dose proportionality...”Publicado no Drug Des Devel Ther (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
13
Por de Farias, Pablo Antonio Maia, Figueredo, Fernando Gomes, Lucas, Aline Maria Brito, de Moura, Rafael Barbosa, Coutinho, Henrique Douglas Melo, da Silva, Tania Maria Sarmento, Martin, Ana Luiza de Aguiar Rocha, Fonteles, Marta Maria de França
Publicado no Drug Des Devel Ther (2015)
“... in the drug dose required and possibly in consequent adverse events for patients....”Publicado no Drug Des Devel Ther (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
14
Por de Oliveira Magalhães, Uiaran, de Souza, Alessandra Mendonça Teles, Albuquerque, Magaly Girão, de Brito, Monique Araújo, Bello, Murilo Lamim, Cabral, Lucio Mendes, Rodrigues, Carlos Rangel
Publicado em 2013
“... immunodeficiency virus (HIV). Treatment with antiretroviral drugs is the best option for viral suppression...”Publicado em 2013
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
15
“... it might be a neuroprotective and disease-modifying drug. Data from ongoing clinical trials of pridopidine...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
16
Por Wang, Ying, Sun, Sheng-Gang, Zhu, Sui-Qiang, Liu, Chun-Feng, Liu, Yi-Ming, Di, Qing, Shang, Hui-Fang, Ren, Yan, Xiang, Wei, Chen, Sheng-Di
Publicado no Drug Des Devel Ther (2016)
“... for Parkinson’s disease (PD). A critical dose level above which a better benefit-to-harm ratio exists has not been...”Publicado no Drug Des Devel Ther (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
17
Por Erturk, Ayse, Adnan Akdogan, Remzi, Parlak, Emine, Cure, Erkan, Cumhur Cure, Medine, Ozturk, Cinar
Publicado em 2014
“... transaminase (ALT) normalization at the end of 4 years. CONCLUSION: Increasing ETV dose from 0.5 mg to 1 mg...”Publicado em 2014
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
18
Por Rezende, Vinicius Marcondes, Rivellis, Ariane, Novaes, Mafalda Megumi Yoshinaga, de Alencar Fisher Chamone, Dalton, Bendit, Israel
Publicado em 2013
“... and Drug Administration and Brazilian National Health Surveillance Agency within the range of 0.500–10.0 μg...”Publicado em 2013
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
19
“.... Nonsteroidal anti-inflammatory drugs (NSAIDs) play an essential role associated with their analgesic potency...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
20
Por Min, Jee Sun, Kim, Doyun, Park, Jung Bae, Heo, Hyunjin, Bae, Soo Hyeon, Seo, Jae Hong, Oh, Euichaul, Bae, Soo Kyung
Publicado no Drug Des Devel Ther (2016)
“...BACKGROUND: Evaluating the potential risk of metabolic drug–drug interactions (DDIs) is clinically...”Publicado no Drug Des Devel Ther (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo